Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03292718
Other study ID # s60787
Secondary ID
Status Not yet recruiting
Phase N/A
First received September 20, 2017
Last updated September 20, 2017
Start date October 2017
Est. completion date December 2018

Study information

Verified date September 2017
Source Universitaire Ziekenhuizen Leuven
Contact Mieke Boon, MD PhD
Phone +3216343820
Email mieke.boon@uzleuven.be
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Interventional trial to study the influence of the use of MyCyFAPP (mobile application) on the gastro-intestinal related quality of life.

This mobile APP has been developed during previous workpackages of the Horizon2020 Project and contains several modules:

- mathematical prediction model to calculate the needed dose for pancreatic enzyme replacement therapy

- educational games and other educational material

- communication with doctor/dietician through professional webtool

- diary to register symptoms and data on nutrition.

The app will be introduced and used during 6 months. Primary outcome parameter will be change in modified PedsQL GI after 3 months. PedsQL GI is an existing questionnaire that evaluates gastro-intestinal related quality of life in children. We validated it for use in cystic fibrosis in a previous observational study.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 200
Est. completion date December 2018
Est. primary completion date December 2018
Accepts healthy volunteers No
Gender All
Age group 2 Years to 18 Years
Eligibility Inclusion Criteria:

1. Diagnosis of CF as evidenced by one or more clinical feature consistent with the CF phenotype or positive CF newborn screen AND one or more of the following criteria:

1. A documented sweat chloride = 60 mEq/L by quantitative pilocarpine iontophoresis (QPIT)

2. A documented genotype with two disease-causing mutations in the CFTR gene

2. Having pancreatic insufficiency (stool elastase < 200 mcg/g stool) and using PERT

3. Age = 24 months and < 18 years at screening visit

4. Informed consent by parent or legal guardian; assent for children from age 12 years on

6. Inclusion visit coincides with scheduled routine clinic visit 7. Ability and willingness to comply with APP use and evaluations at time of routine clinic visits as judged by the site investigator 8. Availability of wifi connection at home so that connection to the internet is feasible at home at least weekly.

Exclusion Criteria:

1. Acute infection associated with decreased appetite or fever at time of run-in visit

2. Acute abdominal pain necessitating an intervention at time of run-in visit

3. Physical findings that would compromise the safety of the participant or the quality of the study data as determined by site investigator

4. Investigational drug use within 30 days prior to run-in visit

5. Started with CFTR modulator treatment less than 3 months before start of run-in visit

6. Inability to use the APP due to patient specific factors such as language or learning difficulties

Study Design


Related Conditions & MeSH terms


Intervention

Device:
MyCyFAPP
use of the MycyFAPP with all its features during 6 months

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Universitaire Ziekenhuizen Leuven European Commission, Hospital Universitario La Fe

Outcome

Type Measure Description Time frame Safety issue
Primary change in Modified PedsQL GI Modified PedsQL GI will be assessed at month 0 and month 3 by applying questionnaires to children and their parents 3 months
Secondary change in CFQ-R CFQ-R will be assessed by questionnaires 3 months and 6 months
Secondary change in VAS VAS will be assessed by questionnaires 3 months and 6 months
Secondary change in Modified PedsQL GI Modified PedsQL GI will be assessed at month 0 and month 6 by applying questionnaires to children and their parents 6 months
Secondary change in lung function spirometry will be performed 3 and 6 months
See also
  Status Clinical Trial Phase
Completed NCT03637504 - Feasibility of a Mobile Medication Plan Application in CF Patient Care N/A
Active, not recruiting NCT04602468 - Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER) Phase 4
Completed NCT06109675 - Nutritional Status Assessment of Pediatric Cystic Fibrosis Patients and Effect of Nutrition Education on Nutritional Status N/A
Active, not recruiting NCT04392544 - Intestinal Inflammation in CF Patients
Completed NCT04084041 - Efficacy of Simeox Airway Clearance Therapy in Children With Cystic Fibrosis N/A
Not yet recruiting NCT05493137 - Physical Activity Levels of Parents of Children With Cystic Fibrosis- (PHACTS-CF)
Enrolling by invitation NCT06188988 - Viral Infections and Airway Microbiome in Young Children With Cystic Fibrosis
Recruiting NCT04174664 - Comparison of Different Functional Capacity Tests in Cystic Fibrosis Patients With Acute Pulmonary Exacerbation
Completed NCT04138589 - Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function
Completed NCT03579173 - Determinants of Early Cystic Fibrosis Lung Disease
Recruiting NCT05850351 - Virtual Reality Based Tele-Exercises on Exercise Capacity in Cystic Fibrosis N/A
Completed NCT04463628 - Impacts of the Covid-19 Epidemic and Associated Lockdown Measures on the Management, Health and Behaviors of Cystic Fibrosis Patients During the 2020 Epidemic
Completed NCT04835376 - Percussion Palm Cup: Safety and Usability in Infants and Children With Cystic Fibrosis N/A
Completed NCT04293926 - Heart Rate Variability in Children and Adolescents With Cystic Fibrosis N/A
Completed NCT04987567 - Effect of Antioxidant Docosahexaenoic Acid (DHA) in Cystic Fibrosis Patients N/A
Withdrawn NCT04415268 - Combined Effect of CFTR Protein Modulator Drugs and Exercise in Cystic Fibrosis N/A
Not yet recruiting NCT06066723 - 19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease
Terminated NCT03939065 - Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management N/A
Active, not recruiting NCT04613128 - The PROMISE Pediatric Study 6 to 11 Years Old
Completed NCT06242951 - Cardiopulmonary Fitness in Children With Cystic Fibrosis Compared to Healthy Children

External Links